İyot Refrakter Metastatik Diferansiye Tiroid Karsinomlarında Sorafenib Tedavisinin Etkinliliği ve Güvenliği: Tek Merkez Deneyimi

Cilt: 42 Sayı: 2, 3 1 Haziran 2016
  • Pınar Şişman
  • Mustafa Süveran
  • Ahmet Bilgehan Şahin
  • Özen Özgül
  • Soner Cander
  • Erdinç Ertürk
  • Canan Ersoy
Uludağ Üniversitesi Tıp Fakültesi Dergisi Kapak
Uludağ Üniversitesi Tıp Fakültesi Dergisi
PDF İndir
EN TR

The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience

Öz

Differentiated thyroid carcinomas (DTC) are originated from thyroid follicular epithelial cells and comprises %90 of all thyroid carcinomas. The aim of this study was to assess the efficacy and safety of sorafenib treatment on iodine refractory metastatic differentiated thyroid carcinomas. Six patients who have received sorafenib treatment due to refractory metastatic DTC were included in the study. During follow-up skin rashes were the most frequent adverse effect after sorafenib treatment followed by hypertension, high ventricular rate atrial fibrillation and esophagitis. Skin lesions were mild and occurred in the first month of the treatment, after dose reduction symptoms resolved within 1 month. One patient had died of pericardial effusion and two patients had died of progressive pulmonary metastasis. Progressive disease was observed in 3 patients, stable disease in 1 patient and partial response in 1 patient after treatment.Although the efficacy of sorafenib is higher than the conventional chemotherapeutics, it should be used in experienced centers because of the possible side effects that can develope and patients should be informed about those side effects.

Anahtar Kelimeler

Ayrıntılar

Birincil Dil

İngilizce

Konular

-

Bölüm

-

Yazarlar

Pınar Şişman Bu kişi benim

Mustafa Süveran Bu kişi benim

Ahmet Bilgehan Şahin Bu kişi benim

Özen Özgül Bu kişi benim

Soner Cander Bu kişi benim

Erdinç Ertürk Bu kişi benim

Canan Ersoy Bu kişi benim

Yayımlanma Tarihi

1 Haziran 2016

Gönderilme Tarihi

1 Haziran 2016

Kabul Tarihi

-

Yayımlandığı Sayı

Yıl 2016 Cilt: 42 Sayı: 2, 3

IZ

https://izlik.org/JA82DY56HU

Kaynak Göster

RIS / Bibtex
APA
Şişman, P., Süveran, M., Şahin, A. B., Özgül, Ö., Cander, S., Ertürk, E., & Ersoy, C. (2016). The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience. Journal of Uludağ University Medical Faculty, 42(2, 3), 67-72. https://izlik.org/JA82DY56HU
AMA
1.Şişman P, Süveran M, Şahin AB, vd. The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience. Uludağ Tıp Derg. 2016;42(2, 3):67-72. https://izlik.org/JA82DY56HU
Chicago
Şişman, Pınar, Mustafa Süveran, Ahmet Bilgehan Şahin, vd. 2016. “The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience”. Journal of Uludağ University Medical Faculty 42 (2, 3): 67-72. https://izlik.org/JA82DY56HU.
EndNote
Şişman P, Süveran M, Şahin AB, Özgül Ö, Cander S, Ertürk E, Ersoy C (01 Haziran 2016) The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience. Journal of Uludağ University Medical Faculty 42 2, 3 67–72.
IEEE
[1]P. Şişman vd., “The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience”, Uludağ Tıp Derg, c. 42, sy 2, 3, ss. 67–72, Haz. 2016, [çevrimiçi]. Erişim adresi: https://izlik.org/JA82DY56HU
ISNAD
Şişman, Pınar - Süveran, Mustafa - Şahin, Ahmet Bilgehan - Özgül, Özen - Cander, Soner - Ertürk, Erdinç - Ersoy, Canan. “The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience”. Journal of Uludağ University Medical Faculty 42/2, 3 (01 Haziran 2016): 67-72. https://izlik.org/JA82DY56HU.
JAMA
1.Şişman P, Süveran M, Şahin AB, Özgül Ö, Cander S, Ertürk E, Ersoy C. The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience. Uludağ Tıp Derg. 2016;42:67–72.
MLA
Şişman, Pınar, vd. “The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience”. Journal of Uludağ University Medical Faculty, c. 42, sy 2, 3, Haziran 2016, ss. 67-72, https://izlik.org/JA82DY56HU.
Vancouver
1.Pınar Şişman, Mustafa Süveran, Ahmet Bilgehan Şahin, Özen Özgül, Soner Cander, Erdinç Ertürk, Canan Ersoy. The Efficacy and Safety of Sorafenib Treatment on Radioiodine-Reftactory Metastatic Differantiated Thyroid Carcinomas: A Single Center Experience. Uludağ Tıp Derg [Internet]. 01 Haziran 2016;42(2, 3):67-72. Erişim adresi: https://izlik.org/JA82DY56HU

ISSN: 1300-414X, e-ISSN: 2645-9027

Uludağ Üniversitesi Tıp Fakültesi Dergisi "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License" ile lisanslanmaktadır.


Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

2023